Skip to Main Content

Paper Details

Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.
J Am Coll Cardiol
2
2023
Dapagliflozin, IS, MI, PCSK9, Patients, T2DM, Type 2 Diabetes Mellitus, atherothrombosis, atherothrombotic events, dapagliflozin, glucose, ischemic stroke, myocardial infarction, patients, proprotein convertase, sodium, sodium-glucose cotransporter-2, subtilisin/kexin type 9, type 2 diabetes mellitus
Author NameAffiliation
Benjamin M SciricaBrigham and Women's Hospital, Harvard Medical School
David A MorrowIcahn School of Medicine at Mount Sinai Health System
David A MorrowIcahn School of Medicine at Mount Sinai Health System
Deepak L BhattHadassah Hebrew University Hospital
Robert P GiuglianoBrigham and Women's Hospital, Harvard Medical School
Eugene BraunwaldBrigham and Women's Hospital, Harvard Medical School
Marc S SabatineBrigham and Women's Hospital, Harvard Medical School
Marc S SabatineBrigham and Women's Hospital, Harvard Medical School
  • 1 - 8

Datasets

Release 1.2